Trials / Completed
CompletedNCT01842672
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- New York Medical College · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Lymphoblastic Lymphoma
- Diffuse Large B-cell Lymphoma
- Burkitt Lymphoma/Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clofarabine | Dose Escalation of Clofarabine |
| DRUG | Mitoxantrone |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2021-08-01
- Completion
- 2022-09-01
- First posted
- 2013-04-30
- Last updated
- 2022-10-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01842672. Inclusion in this directory is not an endorsement.